D
Definium Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2019 · IPO 2020
A psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness MoreLess
MindMed is a clinical stage biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. The company aims to be a global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. MindMed operates in the biopharmaceutical market, targeting neurotransmitter pathways that play key roles in brain health disorders. The company's pipeline includes innovative drug candidates, both with and without acute perceptual effects, and digital therapeutics. MindMed serves patients suffering from various brain health disorders, leveraging its industry-leading drug development expertise to harness the therapeutic potential of psychedelics and other novel therapeutic targets. The business model revolves around advancing these drug candidates through clinical trials and eventually bringing them to market, generating revenue through the sale of these therapeutic solutions. The company is headquartered in New York, United States, and is committed to addressing the major unmet medical needs in brain health.
Keywords: biopharmaceutical, brain health, novel drugs, digital therapeutics, clinical stage, neurotransmitter pathways, psychedelics, patient outcomes, drug development, innovative solutions.
Company overview
Definium Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 29
- Open positions
- 20
- Dealroom signal
- 62.6
- Investment activity
- 1 companies · latest Feb 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Definium Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $805M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Oct 2025 | $259M | — | Evercore Partners · Leerink Partners | ↗ |
| POST IPO EQUITYOther financing | Aug 2024 | $75M | — | Leerink Partners | ↗ |
| PRIVATE PLACEMENT VCOther financing | Mar 2024 | $175M | — | Special Situations Funds · Octagon Capital Partners · Soleus Capital · Commodore Capital | ↗ |
| POST IPO DEBTDebt | Aug 2023 | $50M | — | K2 HealthVentures | ↗ |
| POST IPO EQUITYOther financing | Oct 2020 | Canaccord Genuity Group · Canaccord Genuity | — | ||
| IPOOther financing | Mar 2020 | Undisclosed | — | ||
| GROWTH EQUITY VCOther financing | Feb 2020 | Cannell Capital · Canaccord Genuity · Blake Mycoskie · Bail Capital | ↗ | ||
| ANGELOther financing | Dec 2019 | Kevin O'Leary · Bruce Linton | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin |
|---|---|---|
| 2026 | −$155M | — |
| 2025 | −$155M | — |
| 2024 | −$92M | — |
| 2023 | −$84M | — |
| 2022 | −$74M | — |
| 2021 | −$94M | — |
| 2020 | −$33M | — |
Growth signals
Definium Therapeutics website traffic
Latest recorded traffic for Definium Therapeutics is 39K monthly website visits, up 116.7% over the last three months. Definium Therapeutics's team declined 77.7% over the past year.
Hiring
Open positions at Definium Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Definium Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Definium Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Definium Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
22 investors on Definium Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Definium Therapeutics has talent and traffic
team presence
In the news
Latest news about Definium Therapeutics
Recent press, funding announcements, and product moves mentioning Definium Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Definium Therapeutics
An AI-synthesized read of the highest-engagement posts about Definium Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Definium Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.